HLA-B*57 micropolymorphism shapes HLA allele-specific epitope immunogenicity, selection pressure, and HIV immune control

Journal of Virology

Volumn 86, Issue 2, 2012, Pages 919-929

  Kloverpris, Henrik N ^a   Stryhn, Anette ^b   Harndahl, Mikkel ^b   van der Stok, Mary ^c   Payne, Rebecca P ^a   Matthews, Philippa C ^a   Chen, Fabian ^e   Riddell, Lynn ^f   Walker, Bruce D ^c,d   Ndung'u, Thumbi ^c   Buus, Søren ^b   Goulder, Philip ^a,c,d  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c UNIVERSITY OF KWAZULU NATAL   (South Africa)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

^e ROYAL BERKSHIRE HOSPITAL   (United Kingdom)

^f NORTHAMPTON GENERAL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; HLA A ANTIGEN; HLA B ANTIGEN; HLA C ANTIGEN; VIRUS DNA; GAG PROTEIN; HLA B57 ANTIGEN; HLA-B57 ANTIGEN;

ADULT; ALLELE; ARTICLE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; DNA SEQUENCE; GENE; GENETIC POLYMORPHISM; HLA B 57 GENE; HLA B 5702 GENE; HLA B 5703 GENE; HLA B 5801 GENE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOGENICITY; MAJOR CLINICAL STUDY; NONHUMAN; PRIORITY JOURNAL; SOUTH AFRICA; VIRUS LOAD; AFRICA; CLASSIFICATION; COHORT ANALYSIS; GENETIC SELECTION; GENETICS; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOLOGY; PHYSIOLOGY; VIROLOGY;

HUMAN IMMUNODEFICIENCY VIRUS;

AFRICA, SOUTHERN; ALLELES; CD8-POSITIVE T-LYMPHOCYTES; COHORT STUDIES; EPITOPES, T-LYMPHOCYTE; GAG GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; HIV INFECTIONS; HIV-1; HLA-B ANTIGENS; HUMANS; POLYMORPHISM, GENETIC; SELECTION, GENETIC; VIRAL LOAD;

EID: 84856861433     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.06150-11     Document Type: Article

References (59)

1. Altfeld M, Goulder PJ. 2011. The STEP study provides a hint that vaccine induction of the right CD8+T cell responses can facilitate immune control of HIV. J. Infect. Dis. 203:753-755.
2. Archbold JK, et al. 2009. Natural micropolymorphism in human leukocyte antigens provides a basis for genetic control of antigen recognition. J. Exp. Med. 206:209-219.
3. Assarsson E, et al. 2007. A quantitative analysis of the variables affecting the repertoire of T cell specificities recognized after vaccinia virus infection. J. Immunol. 178:7890-7901.
4. Bade-Doding C, et al. 2011. The impact of human leukocyte antigen (HLA) micropolymorphism on ligand specificity within the HLA-B*41 allotypic family. Haematologica 96:110-118.
5. Barber LD, et al. 1997. Polymorphism in the alpha 1 helix of the HLA-B heavy chain can have an overriding influence on peptide-binding specificity. J. Immunol. 158:1660-1669.
6. Benjamini Y, Hochberg Y. 1995. Controlling the false discovery rate: A practical and powerful approach to multiple testing. J. R. Stat. Soc. 57: 289-300.
7. Briggs JA, et al. 2004. The stoichiometry of Gag protein in HIV-1. Nat. Struct. Mol. Biol. 11:672-675.
8. Carlson J, Heckerman D, Shani G. 2009. Estimating false discovery rates for contingency tables. Microsoft, Mountain View, CA.
9. Carr WH, Pando MJ, Parham P. 2005. KIR3DL1 polymorphisms that affectNKcell inhibition by HLA-Bw4 ligand. J. Immunol. 175:5222-5229.
10. Carrington M, O'Brien SJ. 2003. The influence of HLA genotype on AIDS. Annu. Rev. Med. 54:535-551.
11. Costello C, et al. 1999. HLA-B*5703 independently associated with slower HIV-1 disease progression in Rwandan women. AIDS 13: 1990-1991.
12. Crawford H, et al. 2009. Evolution of HLA-B*5703 HIV-1 escape muta-tions in HLA-Bz.ast;5703-positive individuals and their transmission recipients. J. Exp. Med. 206:909-921.
13. Crawford H, et al. 2007. Compensatory mutation partially restores fitness and delays reversion of escape mutation within the immunodominant HLA-B*5703-restricted Gag epitope in chronic human immunodeficiency virus type 1 infection. J. Virol. 81:8346-8351.
14. Culmann B, et al. 1991. Six epitopes reacting with human cytotoxic CD8+T cells in the central region of the HIV-1 NEF protein. J. Immunol. 146:1560-1565.
15. Falk K, et al. 1995. Peptide motifs of HLA-B58, B60, B61, and B62 molecules. Immunogenetics 41:165-168.
16. Feeney ME, et al. 2004. Immune escape precedes breakthrough human immunodeficiency virus type 1 viremia and broadening of the cytotoxic T-lymphocyte response in an HLA-B27-positive long-termnonprogressing child. J. Virol. 78:8927-8930.
17. Fellay J, et al. 2009. Common genetic variation and the control of HIV-1 in humans. PLoS Genet. 5:e1000791.
18. Fellay J, et al. 2007. A whole-genome association study of major determinants for host control of HIV-1. Science 317:944-947.
19. Fitzgerald DW, et al. 2011. An Ad5-vectored HIV-1 vaccine elicits cellmediated immunity but does not affect disease progression in HIV-1-infected male subjects: results from a randomized placebo-controlled trial (the Step Study). J. Infect. Dis. 203:765-772.
20. Frahm N, et al. 2005. HLA-B63 presents HLA-B57/B58-restricted cytotoxic T-lymphocyte epitopes and is associated with low human immunodeficiency virus load. J. Virol. 79:10218-10225.
21. Frahm N, Baker B, Brander C. 2008. Identification and optimal definition of HIV-derived cytotoxic T-lymphocyte (CTL) epitopes for the study of CTL escape, functional avidity and viral evolution, p 3-24. In Korber BT, et al (ed), HIV Molecular Immunology. Theoretical Biology and Biophysics, Los Alamos National Laboratory, Los Alamos, NM.
22. Goulder PJ, et al. 2001. Rapid definition of five novel HLA-A*3002-restricted human immunodeficiency virus-specific cytotoxic T-lymphocyte epitopes by ELISPOT and intracellular cytokine staining assays. J. Virol. 75: 1339-1347.
23. Goulder PJ, et al. 1996. Novel, cross-restricted, conserved, and immunodominant cytotoxic T lymphocyte epitopes in slow progressors in HIV type 1 infection. AIDS Res. Hum. Retroviruses 12:1691-1698.
24. Harndahl M, et al. 2009. Peptide binding to HLA class I molecules: homogenous, high-throughput screening, and affinity assays. J. Biomol. Screen. 14:173-180.
25. Harndahl M, Rasmussen M, Roder G, Buus S. 31 October 2010. Realtime, high-throughput measurements of peptide-MHC-I dissociation using a scintillation proximity assay. J. Immunol. Methods. doi:10.1016/ j.jim.2010.10.012.
26. Honeyborne I, et al. 2007. Control of human immunodeficiency virus type 1 is associated with HLA-B*13 and targeting of multiple gag-specific CD8+T-cell epitopes. J. Virol. 81:3667-3672.
27. Huang KH, et al. 2011. Progression to AIDS in South Africa is associated with both reverting and compensatory viral mutations. PLoS One 6:e19018.
28. Kaslow RA, et al. 1996. Influence of combinations of human major histocompatibility complex genes on the course of HIV-1 infection. Nat. Med. 2:405-411.
29. Kiepiela P, et al. 2004. Dominant influence of HLA-B in mediating the potential co-evolution of HIV and HLA. Nature 432:769-775.
30. Kiepiela P, et al. 2007. CD8+T-cell responses to different HIV proteins have discordant associations with viral load. Nat. Med. 13: 46-53.
31. Koehler RN, et al. 2010. Class I HLA-A*7401 is associated with protection from HIV-1 acquisition and disease progression in Mbeya, Tanzania. J. Infect. Dis. 202:1562-1566.
32. Leisner C, et al. 2008. One-pot, mix-and-read peptide-MHC tetramers. PLoS One 3:e1678.
33. Leslie A, et al. 2005. Transmission and accumulation of CTL escape variants drive negative associations between HIV polymorphisms and HLA. J. Exp. Med. 201:891-902.
34. Leslie A, et al. 2010. Additive contribution of HLA class I alleles in the immune control of HIV-1 infection. J. Virol. 84:9879-9888.
35. Leslie AJ, et al. 2004. HIV evolution: CTL escape mutation and reversion after transmission. Nat. Med. 10:282-289.
36. Macdonald WA, et al. 2003. A naturally selected dimorphism within the HLA-B44 supertype alters class I structure, peptide repertoire, and T cell recognition. J. Exp. Med. 198:679-691.
37. Martin MP, et al. 2007. Innate partnership of HLA-B and KIR3DL1 subtypes against HIV-1. Nat. Genet. 39:733-740.
38. Martinez-Picado J, et al. 2006. Fitness cost of escape mutations in p24 Gag in association with control of human immunodeficiency virus type 1. J. Virol. 80:3617-3623.
39. Matthews PC, et al. 2011. HLA-A*7401-mediated control of HIV viremia is independent of its linkage disequilibrium with HLA-B*5703. J. Immunol. 186:5675-5686.
40. Matthews PC, et al. 2008. Central role of reverting mutations in HLA associations with human immunodeficiency virus set point. J. Virol. 82: 8548-8559.
41. McKinnon LR, et al. 2009. Clade-specific evolution mediated by HLAB*57/5801 in human immunodeficiency virus type 1 clade A1 p24. J. Virol. 83:12636-12642.
42. Migueles SA, et al. 2000. HLA B*5701 is highly associated with restriction of virus replication in a subgroup of HIV-infected long term nonprogressors. Proc. Natl. Acad. Sci. U. S. A. 97:2709-2714.
43. Miles JJ, Douek DC, Price DA. 2011. Bias in the alphabeta T-cell repertoire: implications for disease pathogenesis and vaccination. Immunol. Cell Biol. 89:375-387.
44. O'Connor GM, et al. 2007. Functional polymorphism of the KIR3DL1/S1 receptor on human NK cells. J. Immunol. 178:235-241.
45. Payne RP, et al. 2010. Efficacious early antiviral activity of HIV Gagand Pol-specific HLA-B*2705-restricted CD8+ T cells. J. Virol. 84: 10543-10557.
46. Pereyra F, et al. 2010. The major genetic determinants of HIV-1 control affect HLA class I peptide presentation. Science 330:1551-1557.
47. Rodriguez WR, et al. 2004. CD8+T lymphocyte responses target functionally important regions of protease and integrase in HIV-1 infected subjects. J. Transl. Med. 2:15.
48. Rousseau CM, et al. 2006. Large-scale amplification, cloning and sequencing of near full-length HIV-1 subtype C genomes. J. Virol. Methods 136:118-125.
49. Sacha JB, et al. 2007. Gag-specific CD8+T lymphocytes recognize infected cells before AIDS-virus integration and viral protein expression. J. Immunol. 178:2746-2754.
50. Sacha JB, et al. 2007. Pol-specific CD8+T cells recognize simian immunodeficiency virus-infected cells prior to Nef-mediated major histocompatibility complex class I downregulation. J. Virol. 81: 11703-11712.
51. Schellens IM, Kesmir C, Miedema F, van Baarle D, Borghans JA. 2008. An unanticipated lack of consensus cytotoxic T lymphocyte epitopes in HIV-1 databases: the contribution of prediction programs. AIDS 22:33-37.
52. Shehu-Xhilaga M, Crowe SM, Mak J. 2001. Maintenance of the Gag/ Gag-Pol ratio is important for human immunodeficiency virus type 1 RNA dimerization and viral infectivity. J. Virol. 75:1834-1841.
53. Sidney J, et al. 2008. Quantitative peptide binding motifs for 19 human and mouseMHCclass I molecules derived using positional scanning combinatorial peptide libraries. Immunome Res. 4:2.
54. Tang J, et al. 2008. Human leukocyte antigen class I genotypes in relation to heterosexual HIV type 1 transmission within discordant couples. J. Immunol. 181:2626-2635.
55. Thomas R, et al. 2009. HLA-C cell surface expression and control of HIV/AIDS correlate with a variant upstream of HLA-C. Nat. Genet. 41:1290-1294.
56. Wearsch PA, Cresswell P. 2008. The quality control of MHC class I peptide loading. Curr. Opin. Cell Biol. 20:624-631.
57. Yewdell J, et al. 1999. Generating MHC class I ligands from viral gene products. Immunol. Rev. 172:97-108.
58. Yewdell JW, Bennink JR. 2001. Cut and trim: generating MHC class I peptide ligands. Curr. Opin. Immunol. 13:13-18.
59. Yewdell JW, Haeryfar SM. 2005. Understanding presentation of viral antigens to CD8+T cells in vivo: the key to rational vaccine design. Annu. Rev. Immunol. 23:651-682.